Orexin Antagonist Therapy for Glaucoma IOP Fluctuations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma do not effectively address the role of intraocular pressure (IOP) fluctuations in the progression of the disease, despite evidence showing that these fluctuations are an independent risk factor for glaucoma progression, and there is a lack of understanding of the neurophysiologic basis of IOP fluctuations.
Innovation Solution
Administration of an orexin antagonist, specifically 1-(2-methylbenzoxazol-6-yl)-3-[1,5]naphthyridin-4-yl urea (SB334867), to inhibit orexin activity in the dorsomedial hypothalamus and perifornical region, which is believed to regulate circadian fluctuations in IOP, thereby attenuating these fluctuations and providing a novel approach for treating glaucoma.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stress or pressure
If current glaucoma treatments are used, then IOP can be lowered, but IOP fluctuations are not effectively addressed
Solution Approach 1:
The patent introduces orexin antagonists as intermediary substances that block the neurophysiologic pathway between the SCN and IOP regulatory mechanisms. By targeting orexin receptors, these compounds mediate the suppression of circadian IOP fluctuations without directly altering IOP levels, thus stabilizing pressure variability while maintaining therapeutic IOP ranges.
Solution Approach 2:
The invention changes the therapeutic parameter from单纯 IOP level control to IOP fluctuation control by targeting the underlying neurophysiologic mechanism. Orexin antagonists modify the circadian rhythm parameter of IOP, transforming the treatment approach from static pressure management to dynamic fluctuation management.
2Reliability
If orexin antagonists are administered, then IOP fluctuations are reduced, but the mechanism is based on incomplete understanding of neurophysiologic basis
Solution Approach 1:
The patent applies preliminary action by administering orexin antagonists before the circadian peak IOP fluctuation occurs. This preventive approach targets the neurophysiologic pathway upstream of the pressure fluctuation, blocking orexin-mediated signaling from the SCN before it can trigger the IOP surge, thus preventing rather than merely responding to fluctuations.
3Adaptability or versatility
If IOP is lowered in all patients, then treatment coverage is increased, but normal IOP patients may be unnecessarily treated
Solution Approach 1:
The patent applies local quality by targeting the specific neurophysiologic mechanism (orexin pathway) responsible for IOP fluctuations rather than applying universal IOP-lowering treatment. This allows selective intervention in patients with orexin-mediated circadian fluctuations, regardless of their baseline IOP level, thus customizing treatment to the specific pathophysiologic mechanism present in each patient.
Data Source
Figure 1A~1C
Figure 1D~1E
Figure 2A~2B
AI summary
A method is provided for treating patients suffering from elevated intraocular pressure or fluctuation in intraocular pressure, including for example glaucoma patients. The method comprises administered to the patient an inhibitor of orexin activity in an amount sufficient to reduce intraocular pressure or intraocular pressure fluctuation in one or both eyes of the patient.